查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837112

经导管栓塞和封堵装置市场（按产品类型、材料、技术、应用和最终用户划分）—2025-2032 年全球预测

Transcatheter Embolization & Occlusion Device Market by Product Type, Material, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，经导管栓塞和封堵装置市场规模将达到 160.3 亿美元，复合年增长率为 13.19%。

主要市场统计数据
基准年2024年 59.4亿美元
预计2025年 67.3亿美元
预测年份：2032年 160.3亿美元
复合年增长率（%） 13.19%

经导管栓塞和封堵装置的策略性引入是微创血管治疗发展的关键驱动力

在血管微创治疗日益普及的背景下，经导管栓塞和封堵装置已成为融合先进材料科学和精准输送系统的基础工具。这些装置旨在阻断各种临床适应症中的病理性血流，并与介入放射学、血管外科和血管内神经外科工作流程交叉。这源自于临床上对兼具疗效、精准输送和可预测生物相容性的治疗方案日益增长的需求。随着临床医生越来越重视门诊病人路径和缩短手术时间，装置设计人员正在透过创新来应对这项挑战，以简化操作、增强影像下的可视性并改善部署过程中的控制。

器械外形规格的不断演变，使其治疗范围从止血和子宫肌瘤栓塞等传统应用扩展到肝臟、週边血管和神经血管介入治疗。同时，手术团队正在整合微导管技术与混合输送策略，以适应复杂的解剖结构并实现持久的闭塞。监管机构持续改善微创解决方案的路径，鼓励製造商兼顾临床证据产生和上市后监管。这些因素共同再形成了临床演算法和商业模式，要求研发、临床营运和市场进入职能部门之间更紧密的合作，以确保新产品能够显着改善患者预后并提高营运效率。

生物材料、输送系统和手术流程的最新进展如何从根本上改变栓塞的临床和商业策略

栓塞和阻塞设备领域正处于一场变革性变革之中，这场变革由生物材料、输送系统和手术实践的进步共同推动。材料科学的突破正在催生下一代液体栓塞剂和微球，它们具有更可预测的聚合性、更强的渗透性和可调的吸收特性，从而扩大了治疗方案并提高了安全係数。同时，包括血管栓塞和可脱性弹簧圈在内的机械封堵技术正在不断改进，以平衡血栓形成和血管保护，从而能够针对各种解剖挑战提供客製化解决方案。

微导管设计和血流导向输送系统的同步改进降低了手术复杂性并提高了药物部署的准确性。这些技术进步透过增强的成像和术中引导工具进一步放大，从而降低了设备移位的风险并提高了闭塞完整性。事实上，临床医生正在采用多模态策略——跨平台结合设备和材料——以在复杂病例中取得持久的效果。从商业性，这些技术进步也在推动与医疗保健系统基于价值观的对话，强调总治疗成本、手术吞吐量和长期临床耐用性，而不仅仅是医疗设备价格。因此，製造商正在重新调整其产品组合策略，优先考虑互通性、培训支援以及产生能够证明现实世界和经济效益的证据。

全面评估不断变化的贸易政策如何再形成栓塞设备相关人员的采购、製造决策和市场准入

近期源自美国的关税为全球医疗设备供应链带来了新的复杂性，并对製造商、经销商和医疗保健系统产生了连锁反应。关税可能会改变零件采购和成品进口的成本计算，促使企业做出策略转变，例如迁移组装业务、寻找替代供应商以及加强垂直整合，以保持利润率和供应的连续性。对于依赖跨境采购特殊聚合物、金属、微导管组件和影像相容标记的公司而言，这些政策变更可能会延长前置作业时间，因为供应商会重新评估其路线和库存政策。

累积的营运影响不仅限于单位成本。采购团队必须调整合约条款和库存策略，以应对关税波动；监管和品质部门必须在製造地点或零件供应商发生变化时检验设备配置。由于製造商优先考虑条款较优惠的市场，临床医生和医院负责人可能会经历价格动态和分阶段产品推出的变化。此外，关税主导的供应再平衡可能会加速製造业的区域化，鼓励企业将製造地设在更靠近终端市场的地方，以降低贸易风险。因此，策略规划需要跨采购、监管和商业团队的综合情境建模，以确保持续获得​​关键的栓塞和封锁技术，并保护临床的连续性。

可操作的细分情报，展示产品类型、材料和技术如何与临床用例和治疗环境相互作用以影响采用

详细的細項分析揭示了不同产品类型、材料、技术、临床应用和医疗环境之间不同的性能驱动因素和采用障碍，有助于确定製造商和医疗系统的策略重点。按产品类型划分，栓塞弹簧圈（有可拆卸和可推动两种型号）对于机械闭塞至关重要，因为放置精度至关重要；而液体栓塞剂（包括乙烯 - 乙烯醇共聚物和氰基丙烯酸正丁酯配方）则适用于复杂的血管床。微球和颗粒栓塞剂可提供校准的闭塞效果和可预测的远端渗透；而血管栓塞则可为特定解剖结构提供快速的近端血管闭塞。每种产品类别都具有独特的操作特性、影像视觉特性和操作员学习曲线，这些都会影响临床路径的采用。

材料选择进一步区分了器械的性能，因为生物药品通常优先考虑生物相容性和吸收动力学，而合成製剂则注重一致性和长期耐用性。技术模式—血流定向栓塞、机械闭塞和微导管输送系统—与器械选择相互作用，以优化不同适应症的手术效率和疗效持久性。临床应用范围包括止血、肝动脉栓塞、神经血管介入、週边血管闭塞和子宫肌瘤栓塞，其中许多应用对器械的灵活性、闭塞耐用性和栓塞颗粒行为有不同的要求。最后，最终用户环境——门诊手术中心、医院和专科诊所——会影响采购通讯协定、库存管理和培训投资，因此需要根据每种环境量身定制产品配置和服务模式。因此，综合的细分洞察支持有针对性的产品开发、差异化的临床培训以及与特定手术流程和机构采购标准一致的价值提案。

深刻的区域观点，重点在于突出关键区域之间的监管、报销和临床采用差异，以塑造您的策略市场方针

区域动态对临床实务模式、报销框架和供应链架构有着强大的影响，导致各主要地区的优先事项有所不同。在美洲，临床医生的需求通常倾向于快速手术和门诊病人解决方案，强调能够促进高效工作流程和强大培训支援的设备。该地区的监管途径和付款人结构迫使製造商同时证明临床有效性和经济价值，从而影响证据生成策略和商业性通讯。

欧洲、中东和非洲的市场环境碎片化，报销政策、基础设施和临床指南各不相同。这为建立客製化产品系列和合作伙伴关係创造了机会，以满足区域培训需求和采购週期。在亚太地区，介入疗法的快速投资和新的卓越中心正在扩大栓塞疗法的临床应用范围。供应链本地化和与区域经销商建立策略联盟通常是加速产品可及性的优先事项，但产品调整也可能需要符合病患手术偏好和器械註册要求。最终，每个地区在监管复杂性、成本敏感性和临床应用速度之间都有独特的权衡，这要求製造商制定差异化的打入市场策略，并投资于本地证据和培训项目，以实现持续应用。

检验竞争动态以及产品创新、证据产生和通路策略如何决定设备製造商的市场定位

栓塞和阻塞设备领域的竞争态势由产品创新、临床证据、服务产品和通路关係共同驱动。主要企业透过对新一代材料、更优的输送方式和更强大的影像相容性进行有针对性的投资，同时优先考虑临床医生培训和疗效追踪，从而脱颖而出。器材製造商与学术中心和临床网络之间的伙伴关係，对于产生高品质的真实世界证据以及与介入团队建立长期、可信赖的关係，正变得越来越重要。

在市场进入层面，经销商、策略伙伴和直销模式根据治疗领域和最终用户目标，各自拥有独特的优势。将产品创新与全面的培训课程和强大的上市后监测相结合的公司往往能够提高临床医生的忠诚度，并推动更快的采用。此外，能够证明与现有导管平台和成像系统互通性的公司可以减少操作流程中的摩擦，加速采用。竞争定位也取决于能否成功引导医院和门诊中心的采购偏好，并提出与临床结果和营运效率相符的清晰价值提案。综合考虑这些因素，敏捷的创新者和成熟的既有企业必须不断完善其产品才能保持领先地位。

为製造商提供实用的优先建议，以协调产品创新、临床证据和商业性执行，从而加速采用

产业领导者应采取协调产品开发、临床证据和商业性执行的行动方案，以掌握栓塞治疗的长期价值。优先考虑模组化设计并与常用微导管平台相容，以减少操作阻力，并拓展多种适应症的潜在临床应用。投资差异化生物材料和影像标记物，以增强输送控制和可视化。这些技术差异化可以透过结构完善的研究和註册转化为可证实的临床效益。

加强与临床中心的伙伴关係，共同开发培训项目，以提升操作人员的熟练程度并减少治疗结果的差异。同时，重新评估您的供应链布局，以降低关税波动带来的风险，并确保关键零件的冗余。扩大付款方参与度，并明确整体医疗成本效益，重点关注手术时间、併发症减少和下游资源利用率等指标。最后，透过提供灵活的合约、区域证据包和售后整合支持，根据区域和机构层面的细微差别来客製化您的商业性方案。采取这些整合措施可以帮助公司降低采用门槛，在竞争激烈的采购环境中脱颖而出，并在临床和经济效益方面取得可衡量的改善。

我们透明的混合方法研究途径结合了临床证据审查、专家访谈和交叉检验，以提供可靠、可行的见解

本研究整合了同行评审临床文献、器械监管文件、卫生当局指导文件、对介入临床医生和采购负责人的初步访谈以及製造商技术规范的结构化综述，以全面了解栓塞和阻塞设备的动态。资料收集着重于可重复性和资讯来源的三角测量，将关键意见领袖的定性见解与从公开的监管文件和医生主导的註册中提取的器械性能特征相结合。受访者的选择反映了不同的临床专科、执业环境和地理区域，并捕捉了一系列操作偏好和采用考虑因素。

分析方法包括对访谈记录进行主题编码以识别反覆出现的障碍和促成因素，交叉比较设备功能集以评估技术差异，以及情境分析以探索供应炼和政策主导的突发事件。所有研究结果均经过反覆同侪审查检验，并与临床指南和已发表的安全报告进行交叉引用。在考虑製造商提供的声明时，我们会将其与独立的临床证据和监管摘要进行摘要引用，以确保做出平衡的解读。调查方法和资料来源刻意避免依赖任何单一来源，强调混合方法的整合，从而为研发、临床和商业领导层提供可靠且可操作的见解。

综合结论强调了临床、操作和策略要点，这些要点将决定哪些技术将被广泛采用

经导管栓塞和封堵装置占据临床需求、材料创新和系统级经济考量之间的战略枢纽。定义该领域的技术和方法日益成熟，其临床适用性不断扩展，同时也给製造商带来了越来越大的压力，要求其在不同的医疗环境中提供可证明的价值。成功的商业化取决于能否将产品效能与部署现实（例如培训、影像相容性和供应链弹性）结合。此外，贸易和政策的变化凸显了敏捷製造和采购规划在外部衝击下保持设备可用性的重要性。

对于整个生态系统的相关人员来说，前进的道路是明确的：投资临床伙伴关係以建立高品质的证据，优先考虑模组化和可互通的设备设计以减少操作摩擦，并使商业模式与当地医疗保健的实际情况保持一致。透过这样做，公司和医疗系统可以加速安全应用，改善患者治疗效果，并提高手术效率。关注这些优先事项将决定哪些创新将成为标准实践，哪些创新仍将停留在小众领域，从而塑造微创血管治疗的未来。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 生物可吸收栓塞材料的进展改善了长期血管通畅性
  • 整合即时成像模式以增强经导管手术中的导航
  • 开发形状记忆聚合物线圈以控制阻塞并降低迁移风险
  • 利用新型可拆卸微线圈扩展週边血管闭塞应用
  • 开发具有持续释放动力学的针对肿瘤血管的药物释放型栓塞珠
  • 低调输送系统的兴起，允许进入远端和曲折的神经血管解剖结构
  • 栓塞治疗和免疫治疗药物联合治疗的应用日益增多
  • 监管部门的核准推动了整合感测器的下一代封堵器的发展

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 经导管栓塞及封堵装置市场（依产品类型）

  • 栓塞线圈
    • 可拆卸线圈
    • 可推线圈
  • 液态栓塞剂
    • 乙烯 - 乙烯醇共聚物
    • 氰基丙烯酸正丁酯
  • 微球
  • 颗粒栓塞剂
  • 血管栓塞

9. 经导管栓塞及封堵装置市场（依材料）

  • 生物因素
  • 合成因子

10. 经导管栓塞及封堵装置市场（依技术）

  • 血流导栓塞
  • 机械咬合
  • 微导管输送系统

11. 经导管栓塞及封堵装置市场（依应用）

  • 控制出血
  • 肝栓塞
  • 神经血管栓塞
  • 週边血管栓塞
  • 子宫肌瘤栓塞术

12. 经导管栓塞及封堵装置市场（依最终用户）

  • 门诊手术中心
  • 医院
  • 专科诊所

13. 经导管栓塞及封堵装置市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 经导管栓塞及封堵装置市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 经导管栓塞及封堵装置市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Boston Scientific Corporation
    • Medtronic plc
    • Terumo Corporation
    • Johnson & Johnson
    • Cook Medical LLC
    • Merit Medical Systems, Inc.
    • Penumbra, Inc.
    • AngioDynamics, Inc.
    • WL Gore & Associates, Inc.
    • B. Braun Melsungen AG
Product Code: MRR-03168519576B

The Transcatheter Embolization & Occlusion Device Market is projected to grow by USD 16.03 billion at a CAGR of 13.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.94 billion
Estimated Year [2025] USD 6.73 billion
Forecast Year [2032] USD 16.03 billion
CAGR (%) 13.19%

A strategic introduction framing transcatheter embolization and occlusion devices as pivotal drivers of minimally invasive vascular therapy evolution

Transcatheter embolization and occlusion devices have emerged as foundational tools within the broader shift toward less invasive vascular therapies, integrating advanced materials science with precision delivery systems. These devices are engineered to occlude pathological blood flow across a diverse set of clinical indications, and they intersect with interventional radiology, vascular surgery, and endovascular neurosurgery workflows. The landscape is characterized by escalating clinical demand for options that combine efficacy, delivery accuracy, and predictable biocompatibility. As clinicians increasingly prioritize outpatient pathways and shorter procedural times, device designers are responding with innovations that streamline handling, enhance visibility under imaging, and improve controllability during deployment.

The evolution of device form factors has expanded therapeutic reach beyond traditional applications such as hemorrhage control and uterine fibroid embolization to embrace hepatic, peripheral vascular, and neurovascular interventions. Concurrently, procedural teams are integrating microcatheter technologies and hybrid delivery strategies to navigate complex anatomy and achieve durable occlusion. Regulatory authorities continue to refine pathways for minimally invasive solutions, prompting manufacturers to address both clinical evidence generation and post-market surveillance. Taken together, these forces are reshaping clinical algorithms and commercial models, demanding closer alignment among R&D, clinical affairs, and market access functions to ensure that new products deliver measurable improvements in patient outcomes and operational efficiency.

How recent advances in biomaterials, delivery systems, and procedural workflows are fundamentally reshaping clinical practice and commercial strategies in embolization

The landscape for embolization and occlusion devices is in the midst of transformative shifts driven by converging advances in biomaterials, delivery systems, and procedural practice. Material science breakthroughs are enabling next-generation liquid embolics and microspheres that offer more predictable polymerization, enhanced radiopacity, and tunable resorption profiles, thereby widening therapeutic options and improving safety margins. At the same time, mechanical occlusion technologies including vascular plugs and detachable coils are being refined to balance thrombogenicity with vessel preservation, enabling tailored solutions for diverse anatomic challenges.

Parallel improvements in microcatheter design and flow-directed delivery systems are lowering procedural complexity and increasing the precision of agent deployment. These technological gains are amplified by enhanced imaging modalities and intra-procedural guidance tools that together reduce device migration risk and improve occlusion completeness. In practice, clinicians are adopting multimodal strategies-combining devices and materials across platforms-to achieve durable outcomes in complex cases. Commercially, these technical evolutions are prompting value-based conversations with health systems that emphasize total cost of care, procedural throughput, and long-term clinical durability rather than device price alone. Consequently, manufacturers are recalibrating portfolio strategies to prioritize interoperability, training support, and evidence generation that demonstrate real-world clinical and economic benefits.

Comprehensive appraisal of how evolving trade policies are reshaping procurement, manufacturing decisions, and market access for embolization device stakeholders

Recent tariff measures originating from the United States have injected fresh complexity into global supply chains for medical devices, with cascading implications for manufacturers, distributors, and health systems. Tariffs alter the cost calculus of component sourcing and finished goods imports, which can prompt strategic shifts such as relocating assembly operations, qualifying alternative suppliers, or increasing vertical integration to preserve margin and supply continuity. For companies reliant on cross-border procurement of specialized polymers, metals, microcatheter components, and imaging-compatible markers, these policy changes can increase lead times as vendors reassess routing and inventory policies.

The cumulative operational impact extends beyond unit costs. Procurement teams are adjusting contract terms and inventory strategies to buffer against tariff volatility, while regulatory and quality functions must revalidate device configurations when manufacturing locations or component suppliers change. Clinicians and hospital purchasers may encounter altered pricing dynamics or phased product introductions as manufacturers prioritize allocations to markets with more favorable trade terms. Moreover, tariff-driven supply rebalancing can accelerate regionalization of manufacturing, encouraging companies to co-locate production nearer to end markets to reduce trade exposure. As a result, strategic planning now requires integrated scenario modeling across procurement, regulatory, and commercial teams to ensure uninterrupted access to critical embolization and occlusion technologies and to protect clinical continuity.

Actionable segmentation intelligence showing how product types, materials, and technologies interplay with clinical use cases and care settings to shape adoption

Deep segmentation analysis reveals distinct performance drivers and adoption barriers across product categories, materials, technologies, clinical applications, and care settings that determine strategic priorities for manufacturers and health systems. Within product types, embolization coils-available as detachable and pushable configurations-remain integral for targeted mechanical occlusion where placement precision is paramount, while liquid embolic agents, including ethylene vinyl alcohol copolymer and N-butyl cyanoacrylate formulations, provide conformable options for complex vascular beds. Microspheres and particulate embolic agents offer calibrated occlusion with predictable distal penetration, and vascular plugs deliver rapid proximal vessel occlusion for certain anatomies. Each product class carries unique handling characteristics, imaging visibility profiles, and operator learning curves that influence clinical pathway adoption.

Material selection further differentiates device performance, as biological agents often emphasize biocompatibility and resorption dynamics, while synthetic agents provide consistency and longer-term permanence. Technology modalities-flow-directed embolization, mechanical occlusion, and microcatheter delivery systems-interact with device choice to optimize procedural efficiency and outcome durability across indications. Clinical applications span hemorrhage control, hepatic embolization, neurovascular interventions, peripheral vascular occlusions, and uterine fibroid embolization, many of which place divergent demands on device flexibility, occlusion permanence, and embolic particle behavior. Finally, end user environments such as ambulatory surgical centers, hospitals, and specialty clinics influence purchasing protocols, inventory management, and training investments, with each setting requiring tailored product configurations and service models. Integrated segmentation insight therefore supports targeted product development, differentiated clinical training, and value propositions that align with specific procedural workflows and institutional procurement criteria.

Insightful regional perspectives highlighting how regulatory, reimbursement, and clinical adoption differences across major territories shape strategic market approaches

Regional dynamics exert a powerful influence on clinical practice patterns, reimbursement frameworks, and supply chain architectures, resulting in divergent priorities across major geographies. In the Americas, clinician demand often favors rapid procedural turnaround and outpatient-capable solutions, prompting emphasis on devices that facilitate efficient workflows and strong training support. Regulatory pathways and payer structures in this region pressure manufacturers to demonstrate both clinical efficacy and economic value, which in turn shapes evidence generation strategies and commercial messaging.

Across Europe, the Middle East & Africa, the market environment is fragmented by heterogeneous reimbursement policies, variable infrastructure, and diverse clinical guidelines. This creates opportunities for regionally adapted product portfolios and collaborative partnerships that address local training needs and procurement cycles. In Asia-Pacific, rapid investments in interventional capacity and emerging centers of excellence are expanding the clinical footprint for embolization therapies. Supply chain localization and strategic alliances with regional distributors are often prioritized to accelerate access, while product adaptations may be needed to match procedural preferences and device registration requirements. Ultimately, each region presents unique trade-offs between regulatory complexity, cost sensitivities, and clinical adoption velocities, requiring manufacturers to deploy differentiated market entry strategies and to invest in local evidence and training programs to achieve sustained uptake.

Examination of competitive dynamics and how product innovation, evidence generation, and channel strategies determine market positioning for device manufacturers

Competitive dynamics in the embolization and occlusion device arena are driven by a combination of product innovation, clinical evidence, service offerings, and channel relationships. Leading companies differentiate through targeted investments in next-generation materials, improved delivery profiles, and enhanced imaging compatibility, while also prioritizing clinician training and outcomes tracking. Partnerships between device manufacturers and academic centers or clinical networks are increasingly important for generating high-quality real-world evidence and building long-term credibility with interventional teams.

At the go-to-market level, distributors, strategic alliances, and direct sales models each offer distinct advantages depending on the therapeutic area and end user target. Companies that pair product innovation with comprehensive training curricula and robust post-market surveillance tend to foster stronger clinician loyalty and faster uptake. Moreover, firms that can demonstrate interoperability with existing catheter platforms and imaging systems reduce procedural friction and accelerate adoption. Competitive positioning also depends on the ability to navigate procurement preferences in hospitals and ambulatory centers, and to present clear value propositions that align with both clinical outcomes and operational efficiencies. Collectively, these factors create a landscape where nimble innovators and established incumbents must continually refine their offerings to sustain leadership.

Practical and prioritized recommendations for manufacturers to align product innovation, clinical evidence, and commercial execution to accelerate adoption

Industry leaders should pursue a coordinated set of actions that align product development, clinical evidence objectives, and commercial execution to capture long-term value in embolization therapies. Prioritize modular design and compatibility with commonly used microcatheter platforms to reduce procedural friction and to broaden clinical applicability across multiple indications. Invest in differentiated biomaterials and imaging markers that enhance delivery control and visualization; these technical distinctions can be translated into demonstrable clinical benefits through well-structured studies and registries.

Strengthen partnerships with clinical centers to co-develop training programs that accelerate operator proficiency and reduce variability in outcomes. Simultaneously, reassess supply chain footprints to mitigate exposure to tariff-driven disruptions and to ensure redundancy for critical components. Expand payer engagement to articulate total cost of care benefits, focusing on metrics such as procedural time, complication reduction, and downstream resource utilization. Finally, tailor commercial approaches to regional and facility-level nuances by offering flexible contracting, local evidence packages, and integrated post-sales support. By taking these integrated steps, companies can reduce adoption barriers, differentiate in competitive procurement environments, and demonstrate measurable improvements in both clinical and economic outcomes.

Transparent mixed-methods research approach combining clinical evidence review, expert interviews, and cross-validation to ensure robust actionable insights

This research synthesizes peer-reviewed clinical literature, device regulatory filings, guidance documents from health authorities, primary interviews with interventional clinicians and procurement leaders, and a structured review of manufacturer technical specifications to create a comprehensive understanding of embolization and occlusion device dynamics. Data collection emphasized reproducibility and source triangulation, combining qualitative insights from key opinion leaders with device performance characteristics extracted from publicly available regulatory submissions and physician-led registries. Interview subjects were selected to reflect a diversity of clinical specialties, practice settings, and geographic regions to capture the breadth of procedural preferences and adoption considerations.

Analytical methods included thematic coding of interview transcripts to identify recurring barriers and enablers, cross-comparison of device feature sets to assess technological differentiation, and scenario analysis to explore supply chain and policy-driven contingencies. All findings were validated through iterative expert review and reconciled against clinical guidelines and published safety reports. Where manufacturer-provided claims were considered, they were corroborated with independent clinical evidence and regulatory summaries to ensure balanced interpretation. The methodology intentionally avoided reliance on single-source commercial data, favoring mixed-methods synthesis to provide robust, actionable insights for R&D, clinical affairs, and commercial leadership.

Concluding synthesis emphasizing clinical, operational, and strategic imperatives that will determine which technologies achieve widespread adoption

Transcatheter embolization and occlusion devices occupy a strategic nexus of clinical need, materials innovation, and system-level economic considerations. The techniques and technologies that define this field are maturing in ways that expand clinical applicability while simultaneously increasing demands on manufacturers to deliver demonstrable value across diverse care settings. Successful commercialization will hinge on an ability to reconcile product performance with pragmatic deployment factors such as training, imaging compatibility, and supply chain resilience. Moreover, trade and policy shifts underscore the importance of agile manufacturing and procurement planning to sustain device availability in the face of external shocks.

For stakeholders across the ecosystem, the path forward is clear: invest in clinical partnerships to build high-quality evidence, prioritize modular and interoperable device designs to reduce procedural friction, and align commercial models with regional healthcare realities. By doing so, companies and health systems can accelerate safe adoption, improve patient outcomes, and enhance procedural efficiency. The collective focus on these priorities will determine which innovations translate into standard practice and which remain niche interventions, shaping the future of minimally invasive vascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in bioresorbable embolic materials improving long-term vessel patency
  • 5.2. Integration of real-time imaging modalities for enhanced navigation during transcatheter procedures
  • 5.3. Development of shape-memory polymer coils offering controlled occlusion and reduced migration risk
  • 5.4. Expansion of peripheral vascular occlusion applications with novel detachable microcoils
  • 5.5. Emergence of drug-eluting embolic beads targeting tumor vasculature with sustained release kinetics
  • 5.6. Rise of low-profile delivery systems enabling access to distal and tortuous neurovascular anatomy
  • 5.7. Increased adoption of combination therapies coupling embolization with immunotherapy agents
  • 5.8. Regulatory approvals driving growth of next-generation occlusion devices with integrated sensors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Embolization & Occlusion Device Market, by Product Type

  • 8.1. Embolization Coils
    • 8.1.1. Detachable Coils
    • 8.1.2. Pushable Coils
  • 8.2. Liquid Embolic Agents
    • 8.2.1. Ethylene Vinyl Alcohol Copolymer
    • 8.2.2. N-Butyl Cyanoacrylate
  • 8.3. Microspheres
  • 8.4. Particulate Embolic Agents
  • 8.5. Vascular Plugs

9. Transcatheter Embolization & Occlusion Device Market, by Material

  • 9.1. Biological Agents
  • 9.2. Synthetic Agents

10. Transcatheter Embolization & Occlusion Device Market, by Technology

  • 10.1. Flow Directed Embolization
  • 10.2. Mechanical Occlusion
  • 10.3. Microcatheter Delivery Systems

11. Transcatheter Embolization & Occlusion Device Market, by Application

  • 11.1. Hemorrhage Control
  • 11.2. Hepatic Embolization
  • 11.3. Neurovascular Embolization
  • 11.4. Peripheral Vascular Embolization
  • 11.5. Uterine Fibroid Embolization

12. Transcatheter Embolization & Occlusion Device Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Transcatheter Embolization & Occlusion Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Transcatheter Embolization & Occlusion Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Transcatheter Embolization & Occlusion Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Boston Scientific Corporation
    • 16.3.2. Medtronic plc
    • 16.3.3. Terumo Corporation
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Cook Medical LLC
    • 16.3.6. Merit Medical Systems, Inc.
    • 16.3.7. Penumbra, Inc.
    • 16.3.8. AngioDynamics, Inc.
    • 16.3.9. W. L. Gore & Associates, Inc.
    • 16.3.10. B. Braun Melsungen AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY ETHYLENE VINYL ALCOHOL COPOLYMER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY N-BUTYL CYANOACRYLATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROSPHERES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PARTICULATE EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY VASCULAR PLUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY BIOLOGICAL AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SYNTHETIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY FLOW DIRECTED EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MECHANICAL OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MICROCATHETER DELIVERY SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEMORRHAGE CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HEPATIC EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY NEUROVASCULAR EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY UTERINE FIBROID EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY EMBOLIZATION COILS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY LIQUID EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY MATERIAL, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA TRANSCATHETER EMBOLIZATION & OCCLUSION DEVICE MARKET SIZE, BY PR